SmofKabiven Extra Amino Elektrolytenvrij inf. emuls. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

smofkabiven extra amino elektrolytenvrij inf. emuls. i.v.

fresenius kabi sa-nv - glycine 18 g; valine 10 g; arginine 20 g; leucine 12 g; serine 11 g; proline 19 g; alanine 23 g; lysine acetate - eq. lysine 2,2 g/506 ml; histidine 5 g; threonine 7,3 g; tryptophan 3,3 g; soya oil 22 g; triglycerides medium chain 22 g; taurine 1,7 g; olive oil 18 g; fish oil rich in omega-3-acids 11 g; glucose monohydrate - eq. glucose 43 g/506 ml; tyrosine 0,66 g; isoleucine 8,3 g; methionine 7,1 g; phenylalanine 8,4 g - emulsion for infusion - alanine 4.6 g; arginine 4 g; glycine 3.6 g; histidine 1 g; isoleucine 1.7 g; leucine 2.4 g; methionine 1.4 g; phenylalanine 1.7 g; proline 3.7 g; serine 2.2 g; taurine 0.33 g; threonine 1.5 g; tryptophan 0.66 g; tyrosine 0.13 g; valine 2.1 g; soya oil 4.4 g; triglycerides medium chain 4.4 g; olive oil 3.7 g; fish oil, rich in omega-3 acids 2.2 g; lysine acetate; glucose monohydrate - combinations

SmofKabiven Extra Amino Elektrolytenvrij inf. emuls. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

smofkabiven extra amino elektrolytenvrij inf. emuls. i.v.

fresenius kabi sa-nv - glycine 18 g; valine 10 g; arginine 20 g; leucine 12 g; serine 11 g; proline 19 g; alanine 23 g; lysine acetate - eq. lysine 2,2 g/506 ml; histidine 5 g; threonine 7,3 g; tryptophan 3,3 g; soya oil 22 g; triglycerides medium chain 22 g; taurine 1,7 g; olive oil 18 g; fish oil rich in omega-3-acids 11 g; glucose monohydrate - eq. glucose 43 g/506 ml; tyrosine 0,66 g; isoleucine 8,3 g; methionine 7,1 g; phenylalanine 8,4 g - emulsion for infusion - alanine 19 g; arginine 16 g; glycine 15 g; histidine 4 g; isoleucine 6.6 g; leucine 9.8 g; methionine 5.7 g; phenylalanine 6.8 g; proline 15 g; serine 8.6 g; taurine 1.3 g; threonine 5.8 g; tryptophan 2.7 g; tyrosine 0.53 g; valine 8.2 g; soya oil 18 g; triglycerides medium chain 18 g; olive oil 15 g; fish oil, rich in omega-3 acids 8.8 g; lysine acetate; glucose monohydrate - combinations

SmofKabiven Extra Amino Elektrolytenvrij inf. emuls. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

smofkabiven extra amino elektrolytenvrij inf. emuls. i.v.

fresenius kabi sa-nv - glycine 18 g; valine 10 g; arginine 20 g; leucine 12 g; serine 11 g; proline 19 g; alanine 23 g; lysine acetate - eq. lysine 2,2 g/506 ml; histidine 5 g; threonine 7,3 g; tryptophan 3,3 g; soya oil 22 g; triglycerides medium chain 22 g; taurine 1,7 g; olive oil 18 g; fish oil rich in omega-3-acids 11 g; glucose monohydrate - eq. glucose 43 g/506 ml; tyrosine 0,66 g; isoleucine 8,3 g; methionine 7,1 g; phenylalanine 8,4 g - emulsion for infusion - alanine 23 g; arginine 20 g; glycine 18 g; histidine 5 g; isoleucine 8.3 g; leucine 12 g; methionine 7.1 g; phenylalanine 8.4 g; proline 19 g; serine 11 g; taurine 1.7 g; threonine 7.3 g; tryptophan 3.3 g; tyrosine 0.66 g; valine 10 g; soya oil 22 g; triglycerides medium chain 22 g; olive oil 18 g; fish oil, rich in omega-3 acids 11 g; lysine acetate; glucose monohydrate - combinations

SmofKabiven Extra Amino Elektrolytenvrij inf. emuls. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

smofkabiven extra amino elektrolytenvrij inf. emuls. i.v.

fresenius kabi sa-nv - glycine 18 g; valine 10 g; arginine 20 g; leucine 12 g; serine 11 g; proline 19 g; alanine 23 g; lysine acetate - eq. lysine 2,2 g/506 ml; histidine 5 g; threonine 7,3 g; tryptophan 3,3 g; soya oil 22 g; triglycerides medium chain 22 g; taurine 1,7 g; olive oil 18 g; fish oil rich in omega-3-acids 11 g; glucose monohydrate - eq. glucose 43 g/506 ml; tyrosine 0,66 g; isoleucine 8,3 g; methionine 7,1 g; phenylalanine 8,4 g - emulsion for infusion - alanine 9.3 g; arginine 7.9 g; glycine 7.3 g; histidine 2 g; isoleucine 3.3 g; leucine 4.9 g; methionine 2.8 g; phenylalanine 3.4 g; proline 7.4 g; serine 4.3 g; taurine 0.66 g; threonine 2.9 g; tryptophan 1.3 g; tyrosine 0.26 g; valine 4.1 g; soya oil 8.8 g; triglycerides medium chain 8.8 g; olive oil 7.3 g; fish oil, rich in omega-3 acids 4.4 g; lysine acetate; glucose monohydrate - combinations

SmofKabiven Extra Amino Elektrolytenvrij inf. emuls. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

smofkabiven extra amino elektrolytenvrij inf. emuls. i.v.

fresenius kabi sa-nv - glycine 18 g; valine 10 g; arginine 20 g; leucine 12 g; serine 11 g; proline 19 g; alanine 23 g; lysine acetate - eq. lysine 2,2 g/506 ml; histidine 5 g; threonine 7,3 g; tryptophan 3,3 g; soya oil 22 g; triglycerides medium chain 22 g; taurine 1,7 g; olive oil 18 g; fish oil rich in omega-3-acids 11 g; glucose monohydrate - eq. glucose 43 g/506 ml; tyrosine 0,66 g; isoleucine 8,3 g; methionine 7,1 g; phenylalanine 8,4 g - emulsion for infusion - alanine 14 g; arginine 12 g; glycine 11 g; histidine 3 g; isoleucine 5 g; leucine 7.3 g; methionine 4.3 g; phenylalanine 5.1 g; proline 11 g; serine 6.5 g; taurine 1 g; threonine 4.4 g; tryptophan 2 g; tyrosine 0.4 g; valine 6.2 g; soya oil 13 g; triglycerides medium chain 13 g; olive oil 11 g; fish oil, rich in omega-3 acids 6.6 g; lysine acetate; glucose monohydrate - combinations

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva European Union - English - EMA (European Medicines Agency)

efavirenz/emtricitabine/tenofovir disoproxil zentiva

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir